In a recent Securities and Exchange Commission (SEC) filing by ETF Managers Group LLC, it has been revealed that the firm has increased its position in SIGA Technologies, Inc. by 229.9% during the fourth quarter of last year. This substantial increase saw the company acquire an additional 49,531 shares of SIGA Technologies, bringing their total ownership to 71,080 shares. The new stake represents approximately 0.10% of SIGA Technologies worth $523,000 as of its most recent SEC filing.
SIGA Technologies is a New York-based biotechnology company that develops vaccines and drugs for the prevention and treatment of infectious diseases. Its main focus is on smallpox and other emerging infectious diseases such as Ebola, Zika, and Lassa fever.
The company recently posted its earnings results for the first quarter that ended on May 4th of this year. Analysts reported earnings per share (EPS) for the quarter at ($.01). Despite this negative result, some market experts are still optimistic about its future potential. Returns on equity were reported to be at 20.68%, indicating a potentially profitable investment opportunity despite current underperformance.
With research analysts predicting average EPS of $1.05 for this year alone, multiple hedge funds could see significant increases in holdings related to SIGA’s stocks and overall stock market value growth if those predictions come true.
If you’re interested in researching further investment opportunities within SIGA or any other hedge fund holdings’ possible insider trades filings in the SEC database should be easily accessible online using HoldingsChannel.com tools.
Overall, while there may be risks associated with investing in biotech firms like SIGA Technologies due to factors such as unpredictable vaccine approval timelines from regulatory agencies or low adoption rates for particular medications that may not perform as expected; with diligent research and careful investing strategies based on sound fundamentals; such companies could prove worthy long-term investments with immense growth potential ahead.
[bs_slider_forecast ticker=”SIGA”]
Institutional Investors Increase Interest in SIGA Technologies
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”SIGA” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]SIGA Technologies: Institutional Investors Show Interest
Institutional investors and hedge funds have recently shown an increased interest in SIGA Technologies, Inc. (NASDAQ:SIGA). Verition Fund Management LLC purchased a new stake in SIGA Technologies during the third quarter of 2022, which was valued at approximately $1,236,000. Exchange Traded Concepts LLC also lifted its share by 53% in the fourth quarter, acquiring additional shares worth around $381,000. Pasadena Private Wealth LLC similarly started investing in SIGA Technologies with purchases exceeding $573,000, owing to the company’s recent growth.
Finally, First Trust Advisors LP upped its stake by over 204% in the last quarter alone. Insider reports suggest that it acquired nearly 200k more shares in this period alone.
Overall, institutional investors and hedge funds now own approximately 44.41% of SIGA Technologies stock. The company opened on Monday at $5.80 per share after seeing a peak of $26.99 per share a year prior and remains relatively steady at this time.
SIGA Technologies is a commercial-stage pharmaceutical company based out of New York that aims to cater to health security-related markets in the United States. Its lead product has been identified as TPOXX – an oral formulation antiviral drug for treating humans diagnosed with smallpox disease caused by variola virus.
The firm concluded recently declared dividends on June 1st that paid out $0.45 per share; this was preceded by shareholders of record being paid from May 16th until ex-dividend dates were announced on May 15th of the previous month.
To get further insight into how other hedge funds are holding SIGA and track future insider trades for this company or others like it – visit HoldingsChannel.com for updates following most recent filings!
